Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia
International Journal of Laboratory Hematology · 2026
DOI: 10.1111/ijlh.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Shruti Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation and Stem Cell Research Centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Mutation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Banaras Hindu University.
Abstract (Originalsprache)
Introduction
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML); yet, diverse molecular responses and resistance persist. BCR::ABL1 kinase‐domain (TKD) mutations constitute just a fraction of this resistance, and the impact of additional somatic mutations on disease progression and early molecular response remains incompletely defined.
Methods
This single‐centre cohort study analyzed 109 NGS‐tested patients with CML, comprising 44 with TKI‐resistant disease and 65 newly diagnosed patients. Targeted next‐generation sequencing using a 135‐gene myeloid panel was performed on 109 patients. An additional pilot subgroup of 30 TKI‐resistant patients underwent BCR::ABL1 kinase‐domain analysis by PCR/Sanger sequencing and was analyzed separately. Molecular response was assessed using BCR::ABL1 transcript levels on the International Scale and interpreted according to ELN 2020 recommendations.
Results
Somatic mutations were identified in 52.3% of TKI‐resistant and 29.2% of newly diagnosed patients. All Cohort 1 blast‐crisis patients were mutation‐positive, and several concurrent abnormalities were more common in Cohort 1 than in Cohort 2, indicating clonal complexity. In Cohort 2, MMR was achieved in 28/39 (71.8%) mutation‐negative and 6/13 (46.2%) mutation‐positive patients. Mutation‐positivity at baseline was associated with reduced MMR chances but not statistically significant (odds ratio 0.34; 95% confidence interval 0.09–1.23; p = 0.099). ASXL1 emerged as the most common non‐ABL1 mutation but was not statistically significant.
Conclusions
In this Indian CML cohort, somatic mutations were prevalent in TKI‐resistant disease, linked to advanced phase and clonal complexity, and demonstrated a non‐significant trend toward lower early MMR at diagnosis, highlighting the importance of genomic testing in this context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation and Stem Cell Research Centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
- Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
ORCID-Profile: Shruti Mishra
Förderung
- Banaras Hindu University
Zitieren
APA
Mishra, S., Kumar, K., Kumar, D., Kamak, A., Singh, L., & Kumar, N. (2026). Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70165
Vancouver
Mishra S, Kumar K, Kumar D, Kamak A, Singh L, Kumar N. Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70165
BibTeX
@article{Mishra2026,
author = {Mishra, Shruti and Kumar, Kailash and Kumar, Dinesh and Kamak, Ashwin and Singh, Lovely and Kumar, Nilesh},
title = {Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia},
journal = {International Journal of Laboratory Hematology},
year = {2026},
doi = {10.1111/ijlh.70165}
}
EUVIMED